Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

DAIICHI SANKYO, INC.

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Subsidiary

Established: 2010-01-01

Employees: 10K

Market Cap: $79B

Website: http://daiichisankyo.us

Clinical Trials

A Open-Label, Multiple Ascending Dose Study of DS-3078a, an Oral TORC1/2 Kinase Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

Phase 1

Completed

Conditions: Lymphoma
Advanced Solid Tumor

Interventions: Drug: DS-3078a

First Posted Date: 2012-05-01

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 32

Registration Number: NCT01588678

Locations: 🇺🇸
South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States

Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Subjects With Stable Coronary Artery Disease

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel Maintenance Dose
Drug: Ticagrelor Maintenance Dose
Drug: Prasugrel Loading Dose

First Posted Date: 2012-04-30

Last Posted Date: 2019-01-09

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 110

Registration Number: NCT01587651

Locations: 🇺🇸
Univ. of Florida College Medicine, Jacksonville, Florida, United States
🇺🇸
Clinical Pharmacology Unit of Miami, Miami, Florida, United States
🇺🇸
Progressive Medical Research, Port Orange, Florida, United States

and more 10 locations

Open Label Study to Evaluate Safety and Efficacy of 2 Doses of Quizartinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2

Completed

Conditions: Leukemia, Myeloid, Acute

Interventions: Drug: AC220

First Posted Date: 2012-03-29

Last Posted Date: 2019-12-27

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 76

Registration Number: NCT01565668

Locations: 🇺🇸
UCLA School of Medicine, Los Angeles, California, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 21 locations

Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: PLX3397
Drug: Paclitaxel

First Posted Date: 2012-02-03

Last Posted Date: 2020-07-16

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 74

Registration Number: NCT01525602

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Univeristy of California, San Francisco, San Francisco, California, United States
🇺🇸
University of Colorado, Anschutz Cancer Pavilion, Aurora, Colorado, United States

and more 5 locations

Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: tivantinib
Drug: omeprazole
Drug: s-warfarin
Drug: caffeine
Dietary Supplement: vitamin K
Drug: digoxin
Drug: midazolam

First Posted Date: 2012-01-25

Last Posted Date: 2019-02-12

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 28

Registration Number: NCT01517399

Locations: 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

Phase 1

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: U3-1287
Drug: Trastuzumab
Drug: Placebo
Drug: Paclitaxel

First Posted Date: 2012-01-19

Last Posted Date: 2017-10-18

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 29

Registration Number: NCT01512199

Locations: 🇦🇷
Unidad de Investigación FP Clinical Pharma en Centro Medico Integral Fitz Roy, Acevedo, Ciudad Autónoma de Buenos Aires, Argentina
🇦🇷
Centro Medico San Roque, San Miguel, Tucuman, Argentina
🇦🇷
Hospital Britanico, Buenos Aires, Argentina

and more 5 locations

Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury (ASCI)

Phase 2

Completed

Conditions: Acute Spinal Cord Injury

Interventions: Drug: SUN13837 injection
Drug: Placebo

First Posted Date: 2012-01-02

Last Posted Date: 2021-01-15

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 65

Registration Number: NCT01502631

Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: PLX3397

First Posted Date: 2011-12-26

Last Posted Date: 2020-03-04

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 6

Registration Number: NCT01499043

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy

Phase 2

Completed

Conditions: Diabetic Peripheral Neuropathy

Interventions: Drug: DS-5565 tablet
Drug: pregabalin capsule
Drug: placebo capsule
Drug: Placebo tablet

First Posted Date: 2011-12-21

Last Posted Date: 2021-01-05

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 452

Registration Number: NCT01496365

Observational Study to Evaluate the Simplified-STroke REhabilitation Assessment of Movement (S-STREAM) Scale in Subjects Who Have Experienced a Nonhemorrhagic Ischemic Stroke

Completed

Conditions: Motor Function
Nonhemorrhagic Ischemic Stroke

Interventions: Other: Observational study

First Posted Date: 2011-12-21

Last Posted Date: 2021-02-03

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 120

Registration Number: NCT01496885

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy